Home
contact us  /  email
about us
portfolio
team
news
Jun 26, 2016
Coherus BioSciences advances differentiated IP strategy for Humira market access
GLOBE NEWSWIRE
REDWOOD CITY, Calif., May 26, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that the United States Patent and Trademark Office (USPTO) issued to Coherus U.S. Patents 9,340,611; 9,340,612 and 9,346,880. These patents generally concern formulations of adalimumab, the active biological ingredient in Coherus’ Humira biosimilar, CHS-1420, currently in Phase 3.   more >>
May 23, 2016
Coherus Prices Public Offering of the Common Stock
GLOBE NEWSWIRE
REDWOOD CITY, Calif., May 23, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced the pricing of its underwritten public offering of 3,500,000 shares of its common stock at a price to the public of $18.00 per share.   more >>
May 17, 2016
Coherus BioSciences Provides Update on ‘135 IPR
GLOBE NEWSWIRE
REDWOOD CITY, Calif., May 17, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it has received a favorable decision from the Patent Trial and Appeal Board (“PTAB”) of the US Patent and Trademark office instituting Coherus’ petition for Inter Partes Review (“IPR”) of AbbVie’s U.S. Patent 8,889,135   more >>
Feb 01, 2016
Coherus announces chs-1701 (neulasta® biosimilar) met both primary endpoints in registration-enabling immunogenicity study
Cherus BioSciences, Inc.
REDWOOD CITY, Calif., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS) today announced that CHS-1701, a proposed biosimilar of Neulasta® (pegfilgrastim), met both primary endpoints in a double-blind, randomized, two-period, parallel-arm clinical study in 303 healthy subjects.   more >>
Nov 16, 2015
Invuity, Inc. (Nasdaq: IVTY) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire
Invuity, Inc. (IVTY), an advanced medical technology company focused on developing Intelligent Photonics™ devices will visit the Nasdaq MarketSite in Times Square in celebration of both its initial public offering earlier this year and the successful launch of its Hidden Scar™ Surgery program for breast cancer surgery, a part of the company's broader women's health initiative.   more >>
Jun 11, 2015
Invuity Announces Pricing of Initial Public Offering
PR Newswire
SAN FRANCISCO, June 11, 2015 /PRNewswire/ -- Invuity, Inc. today announced the pricing of its initial public offering of 4,000,000 shares of common stock at a public offering price of $12.00 per share, before underwriting discounts and commissions   more >>
Nov 06, 2014
Coherus BioSciences Prices Initial Public Offering of $85 Million of Common Stock
Globe Newswire
Coherus BioSciences, Inc. (Nasdaq:CHRS) announced today the pricing of its initial public offering of 6,296,300 shares of its common stock at a public offering price of $13.50 per share   more >>
Jul 29, 2014
Proteus Digital Health™ Continues to Build Momentum, Most Recent Round of Funding Reaches over $172MM
Proteus Digital Health, Inc., Redwood City, California
Proteus Digital Health, Inc., the leading digital medicines company, today announced that it has completed a second closing of its Series G financing, raising over $172 million and adding additional respected institutional investors.   more >>
Mar 04, 2014
Invuity® Raises $36 Million in Series E Financing
Invuity, Inc., San Francisco, California
Invuity, Inc., a developer of advanced medical devices to dramatically improve access and visualization in minimally invasive and minimal access surgeries, announced today that it has secured $36 million in a Series E financing led by HealthCare Royalty Partners (“HC Royalty”), along with existing investors Valence Life Sciences, InterWest Partners, Kleiner Perkins Caufield and Byers, and a number of other qualified investors.   more >>
Sep 03, 2013
Baxter and Coherus Biosciences Announce Collaboration to Develop and Commercialize Biosimilars
Baxter International, Deerfield, Illinois, and Coherus Biosciences, Redwood City, California
Baxter International Inc. (NYSE:BAX) and Coherus Biosciences, Inc. today announced that they have entered into an exclusive collaboration to develop and commercialize a biosimilar to etanercept   more >>
Jul 26, 2013
Soldiers, Athletes Watched from Inside by Tiny Pill
Bloomberg, USA
Bloomberg TV takes a look at the emerging market of ingestible electronics, including technologies developed by Proteus Digital Health   more >>
Apr 18, 2013
Novation to Offer Invuity® Products to 65,000 Member Hospitals and Affiliates
Invuity, Inc., San Francisco, California
Group Purchasing Agreement Optimizes Invuity’s Sales Force to Support Rapid Multi-Specialty Adoption of EigrTM Illumination Technology   more >>
Apr 11, 2013
NASDAQ Welcomes Chimerix, Inc. to The NASDAQ Stock Market
The NASDAQ OMX Group, Inc.
The NASDAQ OMX Group, Inc. announces an IPO of Chimerix (CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need.   more >>
Jul 05, 2012
Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd. Announce Worldwide Agreement to Develop Novel Digital Health Products
Proteus Digital Health, Redwood City, California and Otsuka Pharmaceutical Co., Tokyo, Japan
Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd. announced they have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize a new category of medicines.   more >>
May 10, 2012
Coherus Biosciences and Daiichi Sankyo Establish Strategic Collaboration to Develop and Commercialize Biosimilar Candidates
Coherus Biosciences, Redwood City, USA
Coherus BioSciences, Inc. and Daiichi Sankyo, Co. Ltd. announced the execution of an exclusive agreement to develop and commercialize biosimilar forms of etanercept and rituximab in certain Asian countries including Japan   more >>
News archive >>

 
 
© Helix Ventures 2008 – 2015   /   about us   /   portfolio   /   team   /   news   /   contact us